Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288184 · ClinicalTrials.gov registry record · Phase 2
Uric Acid in Essential Hypertension in Children
A Phase 2 study of Essential Hypertension, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00288184 is a Phase 2 study of Essential Hypertension that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 30 participants, below the 800-participant average among 8 other Essential Hypertension trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00288184, a Phase 2 study of Essential Hypertension, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is a randomized, double-blinded, placebo controlled, crossover trial of allopurinol for the treatment of children with newly diagnosed essential hypertension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Allopurinol
Study Locations (1)
Texas
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00288184
The ClinicalTrials.gov registry entry for NCT00288184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 800-participant average among 8 other Essential Hypertension trials with a reported enrollment target (96% lower). The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Essential Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00288184 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00288184 about?
NCT00288184 is a clinical study titled "Uric Acid in Essential Hypertension in Children". The study is a randomized, double-blinded, placebo controlled, crossover trial of allopurinol for the treatment of children with newly diagnosed essential hypertension.
What is the current status of trial NCT00288184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-09. Estimated completion is 2007-08.
What conditions does trial NCT00288184 study?
This clinical trial studies the following conditions: Essential Hypertension.
What interventions are being tested in trial NCT00288184?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG).
Who is sponsoring clinical trial NCT00288184?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00288184 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Essential Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Childhood-Onset Essential Hypertension Natural History Study
RECRUITING
-
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
ACTIVE NOT RECRUITING
-
Hypertension: Prediction of Biofeedback Success
COMPLETED · Phase 1
-
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions
COMPLETED · NA
-
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
COMPLETED · Phase 3
-
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.